

Ref. No.P-66/2025-26/29
August 14, 2025

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Subject: Outcome of Board Meeting held on Thursday, 14th August, 2025

Pursuant to Regulations 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), , we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. 14th August, 2025, has inter-alia, considered and approved the following:

1. Financial results:

Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June 2025. The same has also been reviewed by the Audit Committee in its meeting held today.

Further, Baheti & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2025 and the Board has also taken on record their Limited Review Reports on the said Financial Results.

A copy of the Financial Results along with Limited Review Report for the quarter ended 30th June, 2025, as required under Regulation 33 of the Listing Regulations, is attached.

2. Re-appointment of Mr. Dharendra Dubey (DIN: 01493040) aged 58 years, as the Chairman and Managing Director of the Company, for a period of 5(five) years with effect from 30th November, 2025, subject to approval of shareholders in the ensuing Annual General Meeting.

The disclosure pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as Annexure -A.

3. Appointment of Mr. Vivek Saihgal (DIN 11228713) as an Additional Director in the capacity of Independent Director of the Company to hold office for a term of five years, w.e.f. August 14, 2025 , subject to approval of shareholders in the ensuing Annual General Meeting.

The disclosure pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as Annexure -B.

4. Re-appointment of M/s Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor, Bhopal as Cost Auditor of the Company for the FY 2025-26;

The said Re-appointment of M/s. Sanjay Kasliwal & Associates is in compliance with Section 148 of the Companies Act, 2013 and other applicable provisions, if any, read with Companies (Cost Records and Audit) Rules, 2014. The remuneration payable to M/s Sanjay Kasliwal & Associates shall be placed before the shareholders for ratification at the ensuing Annual General Meeting.

The disclosure pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as Annexure -C

The Meeting of the Board of Directors held today commenced at 3:00 P.M. and concluded at 3:30 P.M.

Kindly take the same on your records.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

Encl: As above



Annexure-A

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR SEBI/HO/CED/PoD2/CIR/P/01SSDATED NOVEMBER 11, 2024:

Name of the Director	Mr. Dharendra Dubey
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment as Chairman cum Managing Director.
Date of appointment/cession (as applicable) & term of appointment	<p>The Board of Directors of the Company at its meeting held today i.e. 14th August 2025 have approved the re-appointment of Dharendra Dubey (DIN: 01493040) as the Chairman cum Managing Director.</p> <p>The tenure of his reappointment will be for a period of 5 years w.e.f 30th November, 2025 to 29th November, 2030, which is subject to approval of the shareholders in the ensuing AGM</p>
Brief Profile	<p>Mr. Dharendra Dubey aged 58 years is the Chairman cum Managing Director of the Company, is an entrepreneur. He is looking after the Marketing, R&D, Administration and procurement. He has been associated with the Company since 1995 as Promoter Director. Spanning more than 30 years' experience, Shri Dharendra Dubey has hands-on wide experience in Biotechnology & Molecular Diagnostic industry in Marketing, R&D, & Day to Day business running. Shri Dharendra Dubey devotes whole time attention to the management of the commercial affairs of the company. He is responsible for the day to day administration of the company and carries out his duties as entrusted to him from time to time by the Board of Directors. He has been instrumental for founding 3B BlackBio, Diagnostic Division and its growth.</p>
Disclosure of relationships between directors (in case of appointment of a director)	Son of Mrs. Mithla Dubey, Non-Executive Director and Brother of Mr. Nikhil Kuber Dubey, Whole-Time Director cum CFO.
Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with BSE circular Number LIST/COM/14/20 18-19 dated June 20, 2018	Mr. Dharendra Dubey is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.






Annexure-B

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR SEBI/HO/CED/POD2/CIR/P/01SSDATED NOVEMBER 11, 2024:

Name of the Director	Shri.Vivek Saihgal
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as an Additional Director in the capacity of Independent Director.
Date of appointment/cancellation (as applicable) & term of appointment	<p>The Board of Directors of the Company at its meeting held today i.e. 14th August 2025 approved the appointment of Shri. Vivek Saihgal.</p> <p>He is appointed as an Independent Director of the Company for a term of 5 (five) consecutive years with w.e.f 14th August 2025 up to 13th August 2030, which is subject to approval of the shareholders in the ensuing AGM.</p>
Brief Profile	<p>Shri. (Capt) Vivek Saihgal aged 65; had completed B.Sc.(Bachelor of Science) from University of Delhi, St Stephens College .Later , he did his M. Sc. in Shipping Management from HumberSide University - (U.K.) along with Post Graduate Diploma in Supply Chain Management from Institute of Chartered Financial Analysts of India and is a Member of Chartered Institute of Logistics & Transport (CMILT India). He started his career with Shipping Corporation of India.</p> <p>With a total of 45 years of managerial, consulting, and teaching experience in (30 years of experience in management, logistics, ports, and terminals), in ocean sailing & handling commodities. He has wide experience in Management of Information System , Analyzing Investment appraisals, Legal Documentation for creation of requisite security, - Financial Management, Marketing, Operations & Liaison with Regulatory authorities, Setting up and managing Marketing, Operational and financial control systems, Deployment of multi-location marketing team, developing service line marketing processes and periodic audits to monitor marketing efficiency.</p> <p>He has also Conducted financial & Commercial appraisals for Capital Investment in Bulk and is well -versed with Setting up, managing multi locational Multimodal Direct and Subcontracted operations, Quality Management System, Process documentation, Quality Policy and Objectives, Monitoring Internal Audits and Handling External Audits as Management</p>





	<p>Representative.</p> <p>He has even worked with Tata Consultancy Services Ltd. as a Domain Consultant for Consultancy-cum-Implementation of an End-to-End Integrated Information Technology System, Business Process Consulting, Implementation of ERP/Software products.</p> <p>Later, he joined academics, Symbiosis Skills and Professional University Pune as an Associate Professor at School of Port, Terminal Management and Logistics Introducing Industry applicable New Programs, Aligning the objectives of the New Programs with Skilling outcomes Presently, he is working with Delhi Skills and Entrepreneurship University.</p>
Disclosure of relationships between directors (in case of appointment of a director)	Not related to any Director of the Company.
Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with BSE circular Number LIST/COM/14/20 18-19 dated June 20, 2018	Shri. Vivek Saihgal is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.






Annexure-C

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR SEBI/HO/CED/PoD2/CIR/P/01SSDATED NOVEMBER 11, 2024:

Name	M/s. Sanjay Kasliwal & Associates
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment
Date of appointment/cessation (as applicable) & term of appointment	Re-appointed as Cost Auditor for FY 2025-26 at the Board meeting held on 14th August, 2025, to issue Cost Audit Report as per the provisions of the Companies Act, 2013
Brief Profile	M/s. Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor, Bhopal (Firm Regd. No. 100888) has experience and expertise in Cost Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company.
Disclosure of relationships between directors (in case of appointment of a director)	NA



3B BLACKBIO DX LIMITED
REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Statement of Standalone Unaudited Financial Results For The Quarter Ended 30-06-2025

(Rs. In Lakhs)

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30-06-2025 (Unaudited)	31-03-2025 (Audited)	30-06-2024 (Unaudited)	31-03-2025 (Audited)
I	Revenue from operations	2035.71	2301.97	1750.69	9052.97
II	Other income	431.42	490.78	367.78	1502.58
III	Total Income (I + II)	2467.13	2792.75	2118.47	10555.55
IV	Expenses:				
	Cost of materials consumed	519.70	681.73	497.34	2475.73
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-	(5.97)	44.04	(45.77)	(36.45)
	Employee benefits expenses	148.81	165.97	128.80	620.97
	Finance costs	0.80	3.20	0.62	9.68
	Depreciation and amortization expense	21.50	19.74	22.00	85.74
	Other expenses	214.35	463.85	136.22	1007.13
	Total expenses (IV)	899.19	1378.53	739.21	4162.80
V	Profit/(loss) before exceptional items and tax (III - IV)	1567.94	1414.22	1379.26	6392.75
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	1567.94	1414.22	1379.26	6392.75
VIII	Tax expense:				
	(1) Current tax	321.90	337.60	305.97	1484.57
	(2) Deferred tax	0.00	152.23	0.00	152.23
IX	Profit (Loss) for the period (VII-VIII)	1246.04	924.39	1073.29	4755.95
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	1246.04	924.39	1073.29	4755.95
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	26421.76	21921.24	21921.24	21921.24
XIV	Earnings per equity share:				
	(1) Basic	14.54	10.79	12.53	55.51
	(2) Diluted	14.54	10.79	12.53	55.51

FOR AND ON BEHALF OF THE BOARD



Nikhil Kuber Dubey
NIKHIL KUBER DUBEY
 WHOLE TIME DIRECTOR
 DIN:00538049

PLACE: BHOPAL
 DATE : 14/08/2025



NOTES ON STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2025

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on August 14, 2025 after being reviewed by the Audit Committee.
2. The Company's Agrochemical Business is seasonal in nature and the performance can be impacted by weather conditions and cropping pattern.
3. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended.
4. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures for the nine months ended December 31, 2024, being the date of the end of the third quarter of the financial year, which were subjected to limited review.
5. All the figures of financials have been rounded off to nearest lakh in rupees.
6. Other expenses for the quarter ended June 30, 2025 includes one-time expenses paid to consultants towards fees for M&A advisory and Due Diligence amounting to 84.06 lac, incurred for the acquisition of Coris Bioconcept SRL, Belgium.
7. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
8. The results of the company are available for investors at www.kilpest.com and www.bseindia.com.


Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended June 30, 2025 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD

PLACE: BHOPAL
DATE: 14/08/2025




NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049



BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141, 4251535

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors of
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and



measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement

For BAHETI & CO.
Chartered Accountants
(Firm Registration No 006287C)



(DEEPAK BAHETI)
Partner

Place: Bhopal
Date: 14/08/2025

Membership No: 075063

UDIN: 25075063BMGYCU1962



3B BLACKBIO DX LIMITED
REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Statement of Consolidated Unaudited Financial Results For The Quarter Ended 30-06-2025

(Rs. In Lakhs)

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30-06-2025 (Unaudited)	31-03-2025 (Audited)	30-06-2024 (Unaudited)	31-03-2025 (Audited)
I	Revenue from operations	2223.46	2249.51	1943.40	9646.86
II	Other income	431.66	494.31	369.10	1508.36
III	Total Income (I + II)	2655.12	2743.82	2312.50	11155.22
IV	Expenses:				
	Cost of materials consumed	561.92	721.92	511.98	2601.02
	Purchases of Stock-in-Trade	0.00	0.00	0	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(5.97)	44.04	(45.77)	(36.45)
	Employee benefits expenses	176.54	190.57	162.15	732.08
	Finance costs	1.05	4.37	0.62	10.85
	Depreciation and amortization expense	27.67	28.05	26.80	108.59
	Other expenses	307.56	500.96	220.99	1339.31
	Total expenses (IV)	1068.77	1489.91	876.77	4755.40
V	Profit/(loss) before exceptional items and tax (III - IV)	1586.35	1253.91	1435.73	6399.82
VI	Exceptional items	0.00	0.00	0	0.00
VII	Profit before tax (V - VI)	1586.35	1253.91	1435.73	6399.82
VIII	Tax expense:				
	(1) Current tax	321.90	298.12	305.97	1478.47
	(2) Deferred tax	0.00	152.24	0	152.24
IX	Profit (Loss) for the period (VII-VIII)	1264.45	803.55	1129.76	4769.11
	Profit or loss, attributable to owners of parent	1258.93	839.81	1112.82	4765.17
	Total profit or loss, attributable to non-controlling interests	5.52	-36.26	16.94	3.95
X	Other Comprehensive Income/(loss)	0.00	0.00	0	0.00
XI	Total Comprehensive Income for the period (IX+X)	1264.45	803.55	1129.76	4769.11
	Profit or loss, attributable to owners of parent	1258.93	839.81	1112.82	4765.17
	Total profit or loss, attributable to non-controlling interests	5.52	-36.26	16.94	3.95
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	26243.65	21690.58	21690.58	21690.58
XIV	Earnings per equity share:				
	(1) Basic	14.76	9.38	13.19	55.66
	(2) Diluted	14.76	9.38	13.19	55.66

FOR AND ON BEHALF OF THE BOARD



Nikhil Kuber Dubey
NIKHIL KUBER DUBEY
 WHOLE TIME DIRECTOR
 DIN:00538049

PLACE: BHOPAL
 DATE : 14/08/2025



NOTES ON CONSOLIDATED UN-AUDITED FINANCIAL RESULT FOR THE QUARTER ENDED 30th JUNE, 2025

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on August 14, 2025 after being reviewed by the Audit Committee.
2. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended;
3. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)
4. The summarized figures for M/s 3B BLACKBIO DX LIMITED (FORMERLY, KILPEST INDIA LIMITED) (Both Agrochemicals and Diagnostic Division) as a standalone entity are:

PARTICULARS	QUARTER ENDED			YEAR ENDED
	30-06-2025	31-03-2025	30-06-2024	31-03-2025
	(unaudited)	(audited)	(unaudited)	(audited)
Total Income (Rs Lakhs)	2467.13	2792.75	2118.47	10555.55
Profit Before Tax (Rs Lakhs)	1567.94	1414.22	1379.26	6392.75
Profit After Tax (Rs Lakhs)	1246.04	924.39	1073.29	4755.95
Basic Earnings Per Share (Rs)	14.54	10.79	12.53	55.51

5. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures for the nine months ended December 31, 2024, being the date of the end of the third quarter of the financial year, which were subjected to limited review.
6. The Consolidated Financials include the Financials of Subsidiary Company also.
7. All the figures of financials have been rounded off to nearest lakh in rupees.
8. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.






9. The Results of the Company are available for investors at www.kilpest.com and www.bseindia.com

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended June 30, 2025 which needs to be explained

FOR AND ON BEHALF OF THE BOARD



PLACE: BHOPAL
DATE: 14/08/2025


NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049



BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141, 4251535

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors of
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

We have reviewed the accompanying Statement of unaudited consolidated financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) ('hereinafter referred to as 'the Holding Company') ,its subsidiary (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2025 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

- i. 3B BlackBio Dx Limited (Formerly, Kilpest India Limited, Holding)
- ii. TRUPCR Europe Limited (Subsidiary)

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The unaudited interim financial results and other unaudited financial information of this subsidiary has not been reviewed by their auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of this subsidiary, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bhopal
Date: 14/08/2025

For BAHETI & CO.
(FRN 006287C)
Chartered Accountants



(DEEPAK BAHETI)
Partner



Membership No.075063

UDIN 25075063BMGYCV3553

3B BLACKBIO DX LIMITED

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL-462 023

CIN:L24211MP1972PLC001131

CONSOLIDATED SEGMENTWISE REVENUE AND RESULTS

(Rs. In Lakhs)

	Quarter ended 30-06-2025 Unaudited	Quarter ended 31-03-2025 Audited	Quarter ended 30-06-2024 Unaudited	Year ended 31-03-2025 Audited
1 Segment Revenue				
(a)Agrochemicals	227.40	301.55	248.96	1218.61
(b) Diagnostic kits	1996.06	1947.96	1694.44	8428.25
Total income from operations (net)	2223.46	2249.51	1943.40	9646.86
2 Segment Results				
(a)Agrochemicals	(4.36)	(56.90)	(2.38)	(9.84)
(b) Diagnostic kits	1591.77	1315.17	1438.73	6420.50
Total Segment Profit before Interest and Tax	1587.40	1258.27	1436.35	6410.66
Less : Interest Expense				
(a)Agrochemicals	0.79	3.20	0.62	9.68
(b) Diagnostic kits	0.26	1.17	0.00	1.17
Profit before Tax	1586.35	1253.90	1435.73	6399.81
3 Segment Assets				
(a)Agrochemicals	2888.30	2718.56	2851.40	2718.56
(b) Diagnostic kits	26798.45	26853.28	23823.88	26853.28
Total Segment Assets	29686.75	29571.84	26675.28	29571.84
4 Segment Liabilities				
(a)Agrochemicals	400.86	225.96	446.25	225.96
(b) Diagnostic kits	920.95	2245.39	2190.98	2245.39
Total Segment Liabilities	1321.81	2471.35	2637.23	2471.35
(a)Agrochemicals	2487.44	2492.60	2405.15	2492.60
(b) Diagnostic kits	25877.50	24607.89	21632.90	24607.89
5 Capital Employed	28364.94	27100.49	24038.05	27100.49

FOR AND ON BEHALF OF THE BOARD



(Handwritten Signature)

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE: BHOPAL
DATE : 14/08/2025